CAN-ASC is a Canada-wide consortium of researchers and clinician scientists. We collaborate with international networks from academia and industry to develop consensus-driven, standardized and validated operating procedures (SOPs) for human immunology research.
For patients and families with unexplained health conditions, genome-wide sequencing can provide much-needed answers, but it can also raise a lot of questions. We are trying to figure out the best ways to provide genetic counselling for genome-wide sequencing in Canada so that we can best support these families. We will be looking into different clinical, ethical, and economic methods to make sure there is equitable access to genetic counselling and testing for all Canadians.
The Maxwell Lab focuses our studies on discovering and targeting molecular pathways that underlie hereditary cancers, understanding how cells grow and move in tissues and tumors, and collaborating and developing prospective personalized medicine in childhood cancers.
Researchers with the Michael Cuccione Childhood Cancer Research Program embrace one goal: to save children’s lives, while improving their health and quality of life through every phase of treatment and recovery.
The BCCHR Trainee Omics Group is a team of enthusiastic trainees from across research themes at the BC Children's Research Institute who are eager to make bioinformatics accessible and fun for everyone!
This week's Research Roundup covers medicinal cannabis and autism, the use of CRISPR to reduce transplant rejection, gender's role in adolescent food choices and the connection between early cytomegalovirus infection and allergies.
This week's Research Roundup covers new targets for treating schizophrenia, improved models of childhood acute lymphoblastic leukemia, game-changing concussion education for educators and a new way to identify concussions using resting state EEG data.
The Gut4Health team at BC Children's Hospital has put a novel twist on a gold standard nutritional treatment for pediatric inflammatory bowel disease. A prebiotic formulation could lead to longer-term remission and improve outcomes for children with IBD.
We believe there’s nothing we can’t do with your support. It can take years to turn scientific breakthrough into new interventions and treatments. Funding helps speed the pace of change. When given the resources, we can bring transformative therapies – and hope – out of the laboratory and into the clinic to save and improve children’s lives.